HR 2883
117th Congress
House
Health
Administrative remedies
Business ethics
Civil actions and liability
Competition and antitrust
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Licensing and registrations
Prescription drugs
Public participation and lobbying
Stop Stalling Access to Affordable Medications
Introduced: April 28, 2021
Introduced by:
Jeffries, Hakeem S.
Democratic
· New York
See on congress.gov
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 29, 2021
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.
Sep 29, 2021
Committee Consideration and Mark-up Session Held.
Apr 28, 2021
Referred to the House Committee on the Judiciary.
Apr 28, 2021
Introduced in House
Plain-English summary
Stop Stalling Access to Affordable Medications
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
What's happening now
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.
Committees of jurisdiction
1